Description
The National Eye Institute (NEI) seeks applications for its Translational Research Program (TRP) to move innovative laboratory discoveries toward therapeutic products for visual system diseases. The program uses a two‑phase, milestone‑driven award structure: an R61 phase (up to 2 years) for projects with strong preliminary data but not yet ready for clinical translation, followed by an R33 phase (up to 4 years, total ≤ 5 years) to advance a single candidate through IND/IDE‑enabling studies, IND/IDE filing, and design of future clinical trials. Applicants must define SMART milestones for both phases, include manufacturing and product‑development plans, and address contingency strategies for potential delays. The award is a grant (R61/R33) limited to U.S. entities; foreign sub‑awards are prohibited. Up to five awards are anticipated.
• Supports biologics, pharmaceuticals, medical devices, or combination therapies for any eye‑related disease.
• R61 phase: ≤ 2 years, up to ~$250 k/year (pre‑clinical development).
• R33 phase: ≤ 4 years, up to ~$500 k/year (IND/IDE preparation, filing, trial design).
• Total project period ≤ 5 years; milestones must be SMART.
• Eligible applicants: U.S. public, private, nonprofit, small‑business, and academic entities (see full eligibility list).
• Estimated award start: Dec 1 2026; submission deadline: Nov 16 2029.